Huntington Disease Clinical Trials 2024

What are the top hospitals conducting huntington disease research?

Huntington's disease, a devastating neurodegenerative disorder, has prompted several leading hospitals to conduct innovative clinical trials in their pursuit of effective treatments. Vanderbilt University Medical Center in Nashville is at the forefront with three ongoing trials focused on Huntington's disease. Since recording its first trial in 2012, this institution has accumulated a total of 11 studies dedicated to understanding and combating this condition. Meanwhile, Sage Investigational Site, located in multiple locations including Boca Raton, Tampa, Washington, and Englewood has also made significant contributions by conducting three active huntington disease trials each across these sites; all began their pursuit just this year during2022.

These dedicated medical centers are actively working towards improving the lives of individuals affected by Huntington's disease through cutting-edge research and development. Through collaborative efforts between patients and healthcare professionals as well as advancements driven by technology and innovation within these top-tier facilities nationwide we're bringing forth rays of hope to those dealing with such debilitating conditions

Which are the best cities for huntington disease clinical trials?

When it comes to huntington disease clinical trials, several cities have emerged as key players in advancing research and treatment options. Baltimore, Maryland; Washington, District of Columbia; Nashville, Tennessee; Birmingham, Alabama; and Englewood, Colorado are at the forefront with active trials. These cities offer individuals battling Huntington's disease access to cutting-edge studies focused on promising interventions such as SAGE-718, intra-striatal rAAV5-miHTT, Tominersen 60 mg, Deutetrabenazine, Valbenazine,and PTC518 among others. With ongoing efforts in these locations,you can find opportunities to participate in innovative clinical trials that hold potential for breakthroughs in Huntington's disease management and care.

Which are the top treatments for huntington disease being explored in clinical trials?

In the quest for effective treatments for Huntington's disease, clinical trials have highlighted several promising options. Leading the way is SAGE-718, currently being explored in two active trials and standing tall with four all-time huntington disease trials since its debut in 2019. Tominersen 60 mg follows closely behind with one ongoing trial, marking its first listing in 2023. Similarly, PTC518 and active tdcs are gaining attention as potential therapies with one active trial each and both first listed in 2022. With researchers dedicating their efforts to these innovative treatments, there is hope on the horizon for individuals living with Huntington's disease.

What are the most recent clinical trials for huntington disease?

Recent clinical trials offer hope in the pursuit of effective treatments for Huntington's disease. Tominersen 60 mg has entered Phase 2, showing promising potential as a therapy for this debilitating condition. Additionally, Cohort 1 (Direct Rollover) is now in Phase 3 and holds great promise in advancing our understanding of Huntington's disease and improving patient outcomes. Another recent trial, SAGE-718, has reached Phase 2 with encouraging results in treating this neurological disorder. Likewise, PTC518 has also shown promise as a potential treatment option during its Phase 2 trial period. These groundbreaking studies pave the way towards new therapeutic approaches that may ultimately transform the lives of individuals affected by Huntington's disease

What huntington disease clinical trials were recently completed?

In the ongoing pursuit of Huntington's disease treatments, several notable clinical trials have recently concluded. In August 2020, Annexon, Inc. completed a trial studying the potential of ANX005 in addressing this debilitating condition. The University of Texas Health Science Center in Houston wrapped up a trial examining the efficacy of Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) back in August 2019. Additionally, Hoffmann-La Roche conducted two significant trials: one investigating RO7234292 (RG6042), which was finalized in April 2019, and another focusing on RO7234292 that concluded in January 2019. These advances underscore the continuous efforts to find effective therapies for Huntington's disease and offer hope to those affected by this challenging disorder.